Richard Fish, MD
Retina Specialist · Houston, TXNPI 1881792844
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,660 of the $5,328 with a category attached, or 68.7%. 12 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 51.1% of the total. Reporting peaked in 2020 at $2,431 and has fallen 97.5% since, to $60 in 2025.
Across 71 payments — averaging $75.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$3K
- Regeneron$2K
- Boston Scientific$359
- AbbVie$241
- Genentech USA, Inc.$189
- Astellas Pharma US Inc$112
- plus $173 from 6 others
What the payments were for
- Consulting fees$3,66069%
- Food & beverage$1,66831%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 21 | $2,724 |
| Regeneron | 2 | $1,529 |
| Boston Scientific | 7 | $359 |
| AbbVie(2 entities) | 18 | $241 |
| Genentech USA, Inc. | 10 | $189 |
| Astellas Pharma US Inc | 4 | $112 |
| Apellis Pharmaceuticals, Inc. | 3 | $52 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Coherus Oncology, Inc. | 1 | $30 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Biogen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$3,660
- GENERAL - THERAPIES$129
- GENERAL VASCULAR ACCESS$102
How this compares
$5,328 in reported general payments places this provider in the 70th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 27 | $1,809 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $211 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Houston
- Garvin DavisHouston$38K
- Ella LeungHouston$12K
- Lindsey HarrisHouston$10K
- Petros CarvounisHouston$8K
- Keith BourgeoisHouston$7K
- Lee TranHouston$4K
- Michael LamHouston$4K
- John AlappattHouston$4K
- Sapa PhamHouston$4K
- Jie GaoHouston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.